



Evolving Paradigm of Curative Intent Breast Cancer Management

Guest Editors:

Dr. Patricia Tang

Tom Baker Cancer Centre,
Calgary, AB T2N 4N2, Canada

Dr. Jeffrey Cao

Tom Baker Cancer Centre,
Calgary, AB T2N 4N2, Canada

Deadline for manuscript
submissions:

closed (30 April 2022)

Message from the Guest Editors

Dear Colleagues,

The care of breast cancer has evolved significantly over the past decade, with personalized medicine and biomarkers influencing decision-making in the curative setting. Within each breast cancer receptor subtype (hormone receptor positive, HER-2 positive, and triple-negative), recent advances are influencing the sequencing of curative therapy. Studies are assessing both escalation and de-escalation of treatment intensity in specific sub-groups of patients. Additional research suggests adjunct lifestyle interventions (such as exercise) also can play a significant role in improving treatment tolerance and compliance, while also impacting cancer outcomes.

This special issue will focus on the current status and challenges in treating breast cancer in the curative setting. It will encompass therapeutic advances in systemic therapy for breast cancer across the receptor subtypes as well as radiotherapy. The role of adjunct lifestyle interventions (both during and after treatment), to help improve the care of breast cancer patients, will also be reviewed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase,** and **other databases.**

Journal Rank: JCR - Q2 (*Oncology*)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currnocol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)